How time of day of immunotherapy infusion affects kidney cancer outcomes
Recent studies have suggested that the time of day when [...]
ASCO GU 2023: A triple combination for previously untreated kidney cancer patients
At the American Society of Clinical Oncology Genitourinary Cancers Conference [...]
ASCO GU 2023: Treatment-free survival for advanced kidney cancer patients on nivolumab and salvage nivolumab/ipilimumab
In this study presented at the American Society of Clinical [...]
Adjuvant nivolumab plus ipilimumab in localised kidney cancer
A recent phase 3 study called CheckMate 914 has shown [...]
Nivolumab plus ipilimumab for advanced kidney cancer after progression on immunotherapy
This phase 2 study looked at the effect on survival [...]
Ipilimumab-nivolumab and axitinib-pembrolizumab combinations produce similar survival times
When ipilimumab plus nivolumab or axitinib plus pembrolizumab are used [...]
A modified nivolumab/ipilimumab dosing regimen
In this phase 3b/4 study, people with advanced kidney cancer [...]
ESMO 2022: Combination of cabozantinib, nivolumab and ipilimumab for patients with advanced kidney cancer with high-risk disease
The results of COSMIC-131 were presented at the European Society [...]
Neutrophil-eosinophil ratio predicts response of kidney cancer to ipilimumab plus nivolumab
Neutrophils and eosinophils are white blood cells. In this study, [...]
Nivolumab plus ipilimumab for localised kidney cancer
In a recent phase 3 clinical trial the combination of [...]
